Radiotherapy dose wasted in compensating for between-treatment tumor growth
10/02/2013
For the first time, researchers have estimated the daily dose of radiotherapy that could be wasted in compensating for cancer cell growth that occurs overnight and during weekends in patients with early breast cancer...
Blood test detects cancer metastasis
10/02/2013
Researchers from the University Gbrbrttingen Institute of Veterinary Medicine and Chronix Biomedical have published a new study exploring the genetic hallmarks of canine mammary cancer...
BerGenBio AS, an oncology biopharmaceutical company, announces that a paper entitled "Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine cross-talk of leukemia cells with bone marrow stroma"[1] by Ben-Batalla et al., has been published in Blood, the most cited peer-reviewed research journal in the field of hematology. The paper reports research directed by Dr...
Merck Serono, the biopharmaceutical division of Merck, has announced that the German cooperative investigator group AIO (Arbeitsgemeinschaft Internistische Onkologie) reported new data from the Phase III head-to-head clinical trial FIRE-3, which show a clinically relevant improvement from Erbitux® (cetuximab) plus FOLFIRI versus bevacizumab plus FOLFIRI as 1st line treatmen...
Melanoma patients treated with ipilimumab can survive up to 10 years
10/01/2013
Patients with advanced melanoma, who have been treated with the monoclonal antibody, ipilimumab, can survive for up to ten years, according to the largest analysis of overall survival for these patients, presented at the 2013 European Cancer Congress (ECC2013) [1]...
The risk of developing and dying from breast and colon cancer increased by diabetes
10/01/2013
Diabetes is linked to an increased risk of developing cancer, and now researchers have performed a unique meta-analysis that excludes all other causes of death and found that diabetic patients not only have an increased risk of developing breast and colon cancer but an even higher risk of dying from them...
Increased mortality risk for younger patients with metastatic colorectal cancer
10/01/2013
Younger patients with colorectal cancer that has spread (metastasised) to other parts of the body represent a high-risk group that is less likely to respond to anti-cancer treatments. Their disease is more likely to progress and they are at greater risk of death than other age groups, according to new reseach presented to the 2013 European Cancer Congress (ECC2013) [1]...
Cancer patients could benefit from the combining of Chinese and Western medicine
10/01/2013
Combining traditional forms of Chinese and Western medicine could offer new hope for developing new treatments for liver, lung, colorectal cancers and osteosarcoma of the bones. Experts from Cardiff University's School of Medicine have joined forces with Peking University in China to test the health benefits of a traditional Chinese medicine...
Merck Serono, the biopharmaceutical division of Merck, has announced that the German cooperative investigator group AIO (Arbeitsgemeinschaft Internistische Onkologie) reported new data from the Phase III head-to-head clinical trial FIRE-3, which show a clinically relevant improvement from Erbitux® (cetuximab) plus FOLFIRI versus bevacizumab plus FOLFIRI as 1st line treatmen...
BerGenBio AS, an oncology biopharmaceutical company, announces that a paper entitled "Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine cross-talk of leukemia cells with bone marrow stroma"[1] by Ben-Batalla et al., has been published in Blood, the most cited peer-reviewed research journal in the field of hematology. The paper reports research directed by Dr...